Clinical Trials

450 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03811002 2026-03-18

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT03811015 2026-03-18

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT04092283 2026-03-18

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07061977 2026-03-18

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Phase 3 Recruiting

336 enrolled

Gynecologic

Locally Advanced Cervical Adenocarcinoma

NCT04267848 2026-03-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

403 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Head & Neck

Nasopharyngeal Carcinoma

NCT00324805 2025-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

1,501 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT01004978 2024-01-03

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

235 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00942331 2023-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

506 enrolled 13 charts

Genitourinary

Carcinoma, Transitional Cell, Prostatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00951496 2021-05-04

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

1,560 enrolled 19 charts

Brenner Tumor

NCT00803062 2019-07-23

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

452 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms

NCT00068692 2018-12-04

Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer